MK-2048 is the Merck & Co. designation for a molecule in its pre-clinical drug discovery that is an integrase inhibitor-class of agent intended to be used against HIV infection. It is a second generation integrase design thought to be superior to the first available integrase inhibitor, raltegravir, in that "MK-2048 has a dissociation half-life of 32 hours on wild-type integrase—more than four times that of raltegravir", and its dissociation half-life against the important HIV integrase mutant N155H was on the same order of magnitude as that of raltegravir against wild-type virus, leading the Merck presenter to suggest the possibility of "reduced susceptibility to resistance mutations" for the second generation drug. MK-2048 is being investigated for use as part of a pre-exposure prophylax
Attributes | Values |
---|
rdf:type
| |
rdfs:label
| - MK-2048 (fr)
- MK-2048 (en)
- MK-2048 (zh)
|
rdfs:comment
| - MK-2048 est une molécule de la classe des anti-intégrase, développée par Merck & Co. Elle est actuellement[Quand ?] en essais cliniques de phase II. La molécule offre un différent de ceux du raltégravir et de l'elvitégravir, et les personnes ayant développé des résistances à ces médicaments pourront donc bénéficier du MK-2048, décrit comme inhibiteur d'intégrase de nouvelle génération. (fr)
- MK-2048系第二代整合酶抑制剂,是抗病毒药品,用于对抗HIV感染。其较前代整合酶抑制剂药物拉替拉韦的优点是,该药物对HIV整合酶的有效抑制时间长达4倍。MK-2048作为暴露前阻断药物(PrEP)的实用性正在研究当中。 MK-2048由默克藥廠开发。 (zh)
- MK-2048 is the Merck & Co. designation for a molecule in its pre-clinical drug discovery that is an integrase inhibitor-class of agent intended to be used against HIV infection. It is a second generation integrase design thought to be superior to the first available integrase inhibitor, raltegravir, in that "MK-2048 has a dissociation half-life of 32 hours on wild-type integrase—more than four times that of raltegravir", and its dissociation half-life against the important HIV integrase mutant N155H was on the same order of magnitude as that of raltegravir against wild-type virus, leading the Merck presenter to suggest the possibility of "reduced susceptibility to resistance mutations" for the second generation drug. MK-2048 is being investigated for use as part of a pre-exposure prophylax (en)
|
foaf:depiction
| |
dcterms:subject
| |
Wikipage page ID
| |
Wikipage revision ID
| |
Link from a Wikipage to another Wikipage
| |
sameAs
| |
dbp:wikiPageUsesTemplate
| |
thumbnail
| |
ATC prefix
| |
c
| |
caption
| |
CAS number
| |
ChEMBL
| |
ChemSpiderID
| |
Cl
| |
F
| |
H
| |
IUPAC name
| |
legal US
| - Investigational New Drug (en)
|
n
| |
O
| |
PubChem
| |
SMILES
| |
StdInChI
| |
StdInChIKey
| - IOYLKNABOQYKKY-JTQLQIEISA-N (en)
|
UNII
| |
has abstract
| - MK-2048 is the Merck & Co. designation for a molecule in its pre-clinical drug discovery that is an integrase inhibitor-class of agent intended to be used against HIV infection. It is a second generation integrase design thought to be superior to the first available integrase inhibitor, raltegravir, in that "MK-2048 has a dissociation half-life of 32 hours on wild-type integrase—more than four times that of raltegravir", and its dissociation half-life against the important HIV integrase mutant N155H was on the same order of magnitude as that of raltegravir against wild-type virus, leading the Merck presenter to suggest the possibility of "reduced susceptibility to resistance mutations" for the second generation drug. MK-2048 is being investigated for use as part of a pre-exposure prophylaxis (PrEP) approach to the treatment of HIV infection. At the time of these reports, there was no indication of the time by which "MK-2048, or related compounds, [would] be ready for clinical trials". (en)
- MK-2048 est une molécule de la classe des anti-intégrase, développée par Merck & Co. Elle est actuellement[Quand ?] en essais cliniques de phase II. La molécule offre un différent de ceux du raltégravir et de l'elvitégravir, et les personnes ayant développé des résistances à ces médicaments pourront donc bénéficier du MK-2048, décrit comme inhibiteur d'intégrase de nouvelle génération. (fr)
- MK-2048系第二代整合酶抑制剂,是抗病毒药品,用于对抗HIV感染。其较前代整合酶抑制剂药物拉替拉韦的优点是,该药物对HIV整合酶的有效抑制时间长达4倍。MK-2048作为暴露前阻断药物(PrEP)的实用性正在研究当中。 MK-2048由默克藥廠开发。 (zh)
|
gold:hypernym
| |
prov:wasDerivedFrom
| |
page length (characters) of wiki page
| |
CAS number
| |
ChEMBL
| |
FDA UNII code
| |
PubChem
| |
foaf:isPrimaryTopicOf
| |
is Link from a Wikipage to another Wikipage
of | |
is foaf:primaryTopic
of | |